ClinicaliQ Trial Snapshot
- REVEAL: A Phase 3 Study of ION582 in Angelman Syndrome — Recruiting • Phase III • NCT06914609.
- ION582 improved seizures, sleep and developmental outcomes in Angelman syndrome patients with UBE3A deletions or mutations.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the efficacy and safety of ION582 in children and adults with Angelman syndrome caused by a deletion or mutation of the UBE3A gene. Conditions: Angelman Syndrome Interventions: ION582, Placebo Lead Sponsor: Ionis Pharmaceuticals, Inc. Planned Enrollment: 158 participants